Top

Published in:

Open Access 01-12-2008 | Review

The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease

Authors: Nibaldo C Inestrosa, Enrique M Toledo

Published in: Molecular Neurodegeneration | Issue 1/2008

Abstract

Recent evidence supports a neuroprotective role for Wnt signaling in neurodegenerative disorders such as Alzheimer's Disease (AD). In fact, a relationship between amyloid-β-peptide (Aβ)-induced neurotoxicity and a decrease in the cytoplasmic levels of β-catenin has been observed. Apparently Aβ binds to the extracellular cysteine-rich domain of the Frizzled receptor (Fz) inhibiting Wnt/β-catenin signaling. Cross-talk with other signaling cascades that regulate Wnt/β-catenin signaling, including the activation of M₁ muscarinic receptor and PKC, the use of Ibuprofen-ChE bi-functional compounds, PPAR α, γ agonists, nicotine and some antioxidants, results in neuroprotection against Aβ. These studies indicate that a sustained loss of Wnt signaling function may be involved in the Aβ-dependent neurodegeneration observed in Alzheimer's brain. In conclusion the activation of the Wnt signaling pathway could be proposed as a therapeutic target for the treatment of AD.

Available only for authorised users

Selkoe DJ: Alzheimer's disease is a synaptic failure. Science. 2002, 298: 789-791. 10.1126/science.1074069.PubMed

Logan CY, Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004, 20: 781-810. 10.1146/annurev.cellbio.20.010403.113126.PubMed

Nusse R: Wnt signaling and stem cell control. Cell Res. 2008, 18: 523-527. 10.1038/cr.2008.47.PubMed

Inestrosa N, De Ferrari GV, Garrido JL, Alvarez A, Olivares GH, Barria MI, Bronfman M, Chacon MA: Wnt signaling involvement in β-amyloid-dependent neurodegeneration. Neurochem Int. 2002, 41: 341-344. 10.1016/S0197-0186(02)00056-6.PubMed

Caricasole A, Copani A, Caruso A, Caraci F, Iacovelli L, Sortino MA, Terstappen GC, Nicoletti F: The Wnt pathway, cell-cycle activation and β-amyloid: novel therapeutic strategies in Alzheimer's disease?. Trends Pharmacol Sci. 2003, 24: 233-238. 10.1016/S0165-6147(03)00100-7.PubMed

Moon RT, Kohn AD, De Ferrari GV, Kaykas A: WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet. 2004, 5: 691-701. 10.1038/nrg1427.PubMed

Gordon MD, Nusse R: Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006, 281: 22429-22433. 10.1074/jbc.R600015200.PubMed

Mikels AJ, Nusse R: Wnts as ligands: processing, secretion and reception. Oncogene. 2006, 25: 7461-7468. 10.1038/sj.onc.1210053.PubMed

Dale TC: Signal transduction by the Wnt family of ligands. Biochem J. 1998, 329 (Pt 2): 209-223.PubMedCentralPubMed

10.

Niehrs C: Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 2006, 25: 7469-7481. 10.1038/sj.onc.1210054.PubMed

11.

Diep DB, Hoen N, Backman M, Machon O, Krauss S: Characterisation of the Wnt antagonists and their response to conditionally activated Wnt signalling in the developing mouse forebrain. Brain Res Dev Brain Res. 2004, 153: 261-270. 10.1016/j.devbrainres.2004.09.008.PubMed

12.

Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C: LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature. 2001, 411: 321-325. 10.1038/35077108.PubMed

13.

Perrimon N, Bernfield M: Specificities of heparan sulphate proteoglycans in developmental processes. Nature. 2000, 404: 725-728. 10.1038/35008000.PubMed

14.

Binari RC, Staveley BE, Johnson WA, Godavarti R, Sasisekharan R, Manoukian AS: Genetic evidence that heparin-like glycosaminoglycans are involved in wingless signaling. Development. 1997, 124: 2623-2632.PubMed

15.

Lin X, Perrimon N: Dally cooperates with Drosophila Frizzled 2 to transduce Wingless signalling. Nature. 1999, 400: 281-284. 10.1038/22343.PubMed

16.

Baeg GH, Lin X, Khare N, Baumgartner S, Perrimon N: Heparan sulfate proteoglycans are critical for the organization of the extracellular distribution of Wingless. Development. 2001, 128: 87-94.PubMed

17.

Colombres M, Henriquez JP, Reig GF, Scheu J, Calderon R, Alvarez A, Brandan E, Inestrosa NC: Heparin activates Wnt signaling for neuronal morphogenesis. J Cell Physiol. 2008, 216: 805-815. 10.1002/jcp.21465.PubMed

18.

Moon RT, DeMarais A, Olson DJ: Responses to Wnt signals in vertebrate embryos may involve changes in cell adhesion and cell movement. J Cell Sci Suppl. 1993, 17: 183-188.PubMed

19.

Du SJ, Purcell SM, Christian JL, McGrew LL, Moon RT: Identification of distinct classes and functional domains of Wnts through expression of wild-type and chimeric proteins in Xenopus embryos. Mol Cell Biol. 1995, 15: 2625-2634.PubMedCentralPubMed

20.

Mikels AJ, Nusse R: Purified Wnt5a protein activates or inhibits β-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006, 4: e115-10.1371/journal.pbio.0040115.PubMedCentralPubMed

21.

Kohn AD, Moon RT: Wnt and calcium signaling: β-catenin-independent pathways. Cell Calcium. 2005, 38: 439-446. 10.1016/j.ceca.2005.06.022.PubMed

22.

Miller JR, Hocking AM, Brown JD, Moon RT: Mechanism and function of signal transduction by the Wnt/β-catenin and Wnt/Ca2+ pathways. Oncogene. 1999, 18: 7860-7872. 10.1038/sj.onc.1203245.PubMed

23.

Kuhl M, Sheldahl LC, Park M, Miller JR, Moon RT: The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet. 2000, 16: 279-283. 10.1016/S0168-9525(00)02028-X.PubMed

24.

De Ferrari GV, Inestrosa NC: Wnt signaling function in Alzheimer's disease. Brain Res Brain Res Rev. 2000, 33: 1-12. 10.1016/S0165-0173(00)00021-7.PubMed

25.

Garrido JL, Godoy JA, Alvarez A, Bronfman M, Inestrosa NC: Protein kinase C inhibits amyloid β peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J. 2002, 16: 1982-1984.PubMed

26.

De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G, Reyes AE, Alvarez A, Bronfman M, Inestrosa NC: Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by β-amyloid fibrils. Mol Psychiatry. 2003, 8: 195-208. 10.1038/sj.mp.4001208.PubMed

27.

Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J: Regulation of tau phosphorylation and protection against β-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord. 2002, 4: 153-165. 10.1034/j.1399-5618.2002.01150.x.PubMed

28.

Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K, Nihonmatsu N, Mercken M, Yamaguchi H, Sugihara S, Wolozin B: Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau. Proc Natl Acad Sci USA. 1998, 95: 9637-9641. 10.1073/pnas.95.16.9637.PubMedCentralPubMed

29.

Zhang Z, Hartmann H, Do VM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Wetering van de M, Clevers H, Saftig P, et al: Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature. 1998, 395: 698-702. 10.1038/27208.PubMed

30.

Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, Storto M, Gaviraghi G, Terstappen GC, Nicoletti F: Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci. 2004, 24: 6021-6027. 10.1523/JNEUROSCI.1381-04.2004.PubMed

31.

Ghanevati M, Miller CA: Phospho-β-Catenin Accumulation in Alzheimer's Disease and in Aggresomes Attributable to Proteasome Dysfunction. J Mol Neurosci. 2005, 25: 79-94. 10.1385/JMN:25:1:079.PubMed

32.

De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, Major MB, Myers A, Saez K, Henriquez JP, Zhao A, et al: Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci USA. 2007, 104: 9434-9439. 10.1073/pnas.0603523104.PubMedCentralPubMed

33.

Magdesian MH, Carvalho MM, Mendes FA, Saraiva LM, Juliano MA, Juliano L, Garcia-Abreu J, Ferreira ST: Amyloid-β binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/β-catenin signaling. J Biol Chem. 2008, 283: 9359-9368. 10.1074/jbc.M707108200.PubMedCentralPubMed

34.

Yu G, Chen F, Levesque G, Nishimura M, Zhang DM, Levesque L, Rogaeva E, Xu D, Liang Y, Duthie M, et al: The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains β-catenin. J Biol Chem. 1998, 273: 16470-16475. 10.1074/jbc.273.26.16470.PubMed

35.

Nishimura M, Yu G, Levesque G, Zhang DM, Ruel L, Chen F, Milman P, Holmes E, Liang Y, Kawarai T, et al: Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of β-catenin, a component of the presenilin protein complex. Nat Med. 1999, 5: 164-169. 10.1038/5526.PubMed

36.

Kang DE, Soriano S, Frosch MP, Collins T, Naruse S, Sisodia SS, Leibowitz G, Levine F, Koo EH: Presenilin 1 facilitates the constitutive turnover of β-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the β-catenin-signaling pathway. J Neurosci. 1999, 19: 4229-4237.PubMed

37.

Inestrosa NC, Alvarez A, Godoy J, Reyes A, De Ferrari GV: Acetylcholinesterase-amyloid-β-peptide interaction and Wnt signaling involvement in Aβ neurotoxicity. Acta Neurol Scand Suppl. 2000, 176: 53-59. 10.1034/j.1600-0404.2000.00308.x.PubMed

38.

Leroy K, Brion JP: Developmental expression and localization of glycogen synthase kinase-3β in rat brain. J Chem Neuroanat. 1999, 16: 279-293. 10.1016/S0891-0618(99)00012-5.PubMed

39.

Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT, Collingridge GL: The role of GSK-3 in synaptic plasticity. Br J Pharmacol. 2008, 153 (Suppl 1): S428-437. 10.1038/bjp.2008.2.PubMedCentralPubMed

40.

Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, et al: LTP inhibits LTD in the hippocampus via regulation of GSK3β. Neuron. 2007, 53: 703-717. 10.1016/j.neuron.2007.01.029.PubMed

41.

Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, Hernandez F, Anderton B, Rosenblum K, Bliss T, et al: Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci. 2007, 25: 81-86. 10.1111/j.1460-9568.2006.05245.x.PubMed

42.

Takahashi M, Tomizawa K, Kato R, Sato K, Uchida T, Fujita SC, Imahori K: Localization and developmental changes of tau protein kinase I/glycogen synthase kinase-3 β in rat brain. J Neurochem. 1994, 63: 245-255.PubMed

43.

Bhat RV, Budd Haeberlein SL, Avila J: Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem. 2004, 89: 1313-1317. 10.1111/j.1471-4159.2004.02422.x.PubMed

44.

Plattner F, Angelo M, Giese KP: The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem. 2006, 281: 25457-25465. 10.1074/jbc.M603469200.PubMed

45.

Avila J, Lucas JJ, Perez M, Hernandez F: Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004, 84: 361-384. 10.1152/physrev.00024.2003.PubMed

46.

Gould TD, Manji HK: Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology. 2005, 30: 1223-1237.PubMed

47.

Ryves WJ, Harwood AJ: Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun. 2001, 280: 720-725. 10.1006/bbrc.2000.4169.PubMed

48.

Grimes CA, Jope RS: The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog Neurobiol. 2001, 65: 391-426. 10.1016/S0301-0082(01)00011-9.PubMed

49.

Harwood AJ: Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Mol Psychiatry. 2005, 10: 117-126. 10.1038/sj.mp.4001618.PubMed

50.

Wada A, Yokoo H, Yanagita T, Kobayashi H: Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sci. 2005, 99: 307-321. 10.1254/jphs.CRJ05009X.PubMed

51.

Nunes PV, Forlenza OV, Gattaz WF: Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry. 2007, 190: 359-360. 10.1192/bjp.bp.106.029868.PubMed

52.

Quintanilla RA, Munoz FJ, Metcalfe MJ, Hitschfeld M, Olivares G, Godoy JA, Inestrosa NC: Trolox and 17β-estradiol protect against amyloid β-peptide neurotoxicity by a mechanism that involves modulation of the Wnt signaling pathway. J Biol Chem. 2005, 280: 11615-11625. 10.1074/jbc.M411936200.PubMed

53.

Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC: Wnt-3a overcomes β-amyloid toxicity in rat hippocampal neurons. Exp Cell Res. 2004, 297: 186-196. 10.1016/j.yexcr.2004.02.028.PubMed

54.

Busciglio J, Lorenzo A, Yeh J, Yankner BA: β-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 1995, 14: 879-888. 10.1016/0896-6273(95)90232-5.PubMed

55.

Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, Ishiguro K, Yamaguchi H: Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid β peptide (25–35) enhances phosphorylation of tau in hippocampal neurons. Neuroscience research. 1998, 31: 317-323. 10.1016/S0168-0102(98)00061-3.PubMed

56.

Sheldahl LC, Slusarski DC, Pandur P, Miller JR, Kuhl M, Moon RT: Dishevelled activates Ca2+ flux, PKC, and CamKII in vertebrate embryos. J Cell Biol. 2003, 161: 769-777. 10.1083/jcb.200211094.PubMedCentralPubMed

57.

De Ferrari GV, Moon RT: The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene. 2006, 25: 7545-7553. 10.1038/sj.onc.1210064.PubMed

58.

Esposito G, Scuderi C, Lu J, Savani C, De Filippis D, Iuvone T, Steardo L, Sheen V, Steardo L: S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J Cell Mol Med. 2008, 12: 914-927. 10.1111/j.1582-4934.2008.00159.x.PubMedCentralPubMed

59.

Mudher A, Lovestone S: Alzheimer's disease-do tauists and baptists finally shake hands?. Trends Neurosci. 2002, 25: 22-26. 10.1016/S0166-2236(00)02031-2.PubMed

60.

Jones SE, Jomary C, Grist J, Stewart HJ, Neal MJ: Modulated expression of secreted frizzled-related proteins in human retinal degeneration. Neuroreport. 2000, 11: 3963-3967.PubMed

61.

Jones SE, Jomary C, Grist J, Stewart HJ, Neal MJ: Altered expression of secreted frizzled-related protein-2 in retinitis pigmentosa retinas. Invest Ophthalmol Vis Sci. 2000, 41: 1297-1301.PubMed

62.

Rattner A, Hsieh JC, Smallwood PM, Gilbert DJ, Copeland NG, Jenkins NA, Nathans J: A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc Natl Acad Sci USA. 1997, 94: 2859-2863. 10.1073/pnas.94.7.2859.PubMedCentralPubMed

63.

Melkonyan HS, Chang WC, Shapiro JP, Mahadevappa M, Fitzpatrick PA, Kiefer MC, Tomei LD, Umansky SR: SARPs: a family of secreted apoptosis-related proteins. Proc Natl Acad Sci USA. 1997, 94: 13636-13641. 10.1073/pnas.94.25.13636.PubMedCentralPubMed

64.

Baranski M, Berdougo E, Sandler JS, Darnell DK, Burrus LW: The dynamic expression pattern of frzb-1 suggests multiple roles in chick development. Dev Biol. 2000, 217: 25-41. 10.1006/dbio.1999.9516.PubMed

65.

Strittmatter WJ, Roses AD: Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA. 1995, 92: 4725-4727. 10.1073/pnas.92.11.4725.PubMedCentralPubMed

66.

Caruso A, Motolese M, Iacovelli L, Caraci F, Copani A, Nicoletti F, Terstappen GC, Gaviraghi G, Caricasole A: Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J Neurochem. 2006, 98: 364-371. 10.1111/j.1471-4159.2006.03867.x.PubMed

67.

Daw EW, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD, Wijsman EM: The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet. 2000, 66: 196-204. 10.1086/302710.PubMedCentralPubMed

68.

de Vrij FM, Fischer DF, van Leeuwen FW, Hol EM: Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog Neurobiol. 2004, 74: 249-270. 10.1016/j.pneurobio.2004.10.001.PubMed

69.

Oddo S: The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med. 2008, 12: 363-373. 10.1111/j.1582-4934.2008.00276.x.PubMedCentralPubMed

70.

Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X: Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002, 108: 837-847. 10.1016/S0092-8674(02)00685-2.PubMed

71.

Aberle H, Bauer A, Stappert J, Kispert A, Kemler R: β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997, 16: 3797-3804. 10.1093/emboj/16.13.3797.PubMedCentralPubMed

72.

Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, Inestrosa NC, Bronfman M: Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem. 2007, 282: 37006-37015. 10.1074/jbc.M700447200.PubMed

73.

Farias GG, Valles AS, Colombres M, Godoy JA, Toledo EM, Lukas RJ, Barrantes FJ, Inestrosa NC: Wnt-7a induces presynaptic colocalization of α7-nicotinic acetylcholine receptors and adenomatous polyposis coli in hippocampal neurons. J Neurosci. 2007, 27: 5313-5325. 10.1523/JNEUROSCI.3934-06.2007.PubMed

74.

Colombres M, Cerpa W, Velarde V, Nibaldo CI: Insulin degrading enzyme (IDE) is a target gene of the Wntsignaling pathway (In Prep). FEBS Lett. 2008,

75.

Arrazola M, Varela-Nallar L, Colombres M, Assar R, Aravena A, Maass A, Martínez S, Inestrosa NC: Calcium/calmodulin-dependent protein kinase type IV (CaMKIV) is a target gene of the Wnt/β-catenin signaling pathway. EMBO Rep. 2008,

76.

Inestrosa N, Colombres M, Assar R, Hodar C, Aravena A, Gonzalez M, Maass A, Martinez S: Detection of Novel WntTarget in the Human Genome. Mol Psychiatry. 2008,

77.

Li H-L, Wang H-H, Liu S-J, Deng Y-Q, Zhang Y-J, Tian Q, Wang X-C, Chen X-Q, Yang Y, Zhang J-Y, et al: Phosphorylation of tau antagonizes apoptosis by stabilizing β-catenin, a mechanism involved in Alzheimer's neurodegeneration. PNAS. 2007, 104: 3591-3596. 10.1073/pnas.0609303104.PubMedCentralPubMed

78.

Wang Y, Thekdi N, Smallwood PM, Macke JP, Nathans J: Frizzled-3 is required for the development of major fiber tracts in the rostral CNS. J Neurosci. 2002, 22: 8563-8573.PubMed

79.

Lyuksyutova AI, Lu C-C, Milanesio N, King LA, Guo N, Wang Y, Nathans J, Tessier-Lavigne M, Zou Y: Anterior-Posterior Guidance of Commissural Axons by Wnt-Frizzled Signaling. Science. 2003, 302: 1984-1988. 10.1126/science.1089610.PubMed

80.

Wang Y, Huso D, Cahill H, Ryugo D, Nathans J: Progressive cerebellar, auditory, and esophageal dysfunction caused by targeted disruption of the frizzled-4 gene. J Neurosci. 2001, 21: 4761-4771.PubMed

81.

Zhao C, Aviles C, Abel RA, Almli CR, McQuillen P, Pleasure SJ: Hippocampal and visuospatial learning defects in mice with a deletion of frizzled 9, a gene in the Williams syndrome deletion interval. Development. 2005, 132: 2917-2927. 10.1242/dev.01871.PubMed

82.

Wang Y, Guo N, Nathans J: The role of Frizzled3 and Frizzled6 in neural tube closure and in the planar polarity of inner-ear sensory hair cells. J Neurosci. 2006, 26: 2147-2156. 10.1523/JNEUROSCI.4698-05.2005.PubMed

83.

Sancho E, Batlle E, Clevers H: Signaling pathways in intestinal development and cancer. Annu Rev Cell Dev Biol. 2004, 20: 695-723. 10.1146/annurev.cellbio.20.010403.092805.PubMed

84.

Polakis P: The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007, 17: 45-51. 10.1016/j.gde.2006.12.007.PubMed

85.

Wang HY, Malbon CC: Wnt-frizzled signaling to G-protein-coupled effectors. Cell Mol Life Sci. 2004, 61: 69-75. 10.1007/s00018-004-4256-z.PubMed

86.

Karasawa T, Yokokura H, Kitajewski J, Lombroso PJ: Frizzled-9 is activated by Wnt-2 and functions in Wnt/β-catenin signaling. J Biol Chem. 2002, 277: 37479-37486. 10.1074/jbc.M205658200.PubMed

87.

Caricasole A, Ferraro T, Iacovelli L, Barletta E, Caruso A, Melchiorri D, Terstappen GC, Nicoletti F: Functional characterization of WNT7A signaling in PC12 cells: interaction with A FZD5 × LRP6 receptor complex and modulation by Dickkopf proteins. J Biol Chem. 2003, 278: 37024-37031. 10.1074/jbc.M300191200.PubMed

88.

Gazit A, Yaniv A, Bafico A, Pramila T, Igarashi M, Kitajewski J, Aaronson SA: Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response. Oncogene. 1999, 18: 5959-5966. 10.1038/sj.onc.1202985.PubMed

89.

Carmon KS, Loose DS: Wnt7a interaction with Fzd5 and detection of signaling activation using a split eGFP. Biochem Biophys Res Commun. 2008, 368: 285-291. 10.1016/j.bbrc.2008.01.088.PubMedCentralPubMed

90.

Shimogori T, VanSant J, Paik E, Grove EA: Members of the Wnt, Fz, and Frp gene families expressed in postnatal mouse cerebral cortex. J Comp Neurol. 2004, 473: 496-510. 10.1002/cne.20135.PubMed

91.

Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway KS, Byrnes EJ, et al: Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2007, 445: 168-176. 10.1038/nature05453.PubMed

92.

Chacon MA, Varela-Nallar L, Inestrosa NC: Frizzled-1 is involved in the neuroprotective effect of Wnt3a against Aβ oligomers. Journal of Cellular Physiology. 2008

93.

Ferreira ST, Vieira MN, De Felice FG: Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life. 2007, 59: 332-345. 10.1080/15216540701283882.PubMed

94.

Magdesian MH, Nery AA, Martins AH, Juliano MA, Juliano L, Ulrich H, Ferreira ST: Peptide blockers of the inhibition of neuronal nicotinic acetylcholine receptors by amyloid β. J Biol Chem. 2005, 280: 31085-31090. 10.1074/jbc.M502406200.PubMed

95.

Geula C, Mesulam MM: Cholinergic systems and related neuropathological predilection patterns in Alzheimer's disease. 1994, Raven Press: New York

96.

Haring R, Gurwitz D, Barg J, Pinkas-Kramarski R, Heldman E, Pittel Z, Wengier A, Meshulam H, Marciano D, Karton Y, et al: Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102B. Biochem Biophys Res Commun. 1994, 203: 652-658. 10.1006/bbrc.1994.2232.PubMed

97.

Genis I, Fisher A, Michaelson DM: Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J Neurochem. 1999, 72: 206-213. 10.1046/j.1471-4159.1999.0720206.x.PubMed

98.

Xie J, Guo Q, Zhu H, Wooten MW, Mattson MP: Protein kinase C iota protects neural cells against apoptosis induced by amyloid β-peptide. Brain Res Mol Brain Res. 2000, 82: 107-113. 10.1016/S0169-328X(00)00187-X.PubMed

99.

Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM: M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice. Neuron. 2006, 49: 671-682. 10.1016/j.neuron.2006.01.020.PubMed

100.

Vlad SC, Miller DR, Kowall NW, Felson DT: Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008, 70: 1672-1677. 10.1212/01.wnl.0000311269.57716.63.PubMedCentralPubMed

101.

Citron M: Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci. 2004, 5: 677-685. 10.1038/nrn1495.PubMed

102.

Morihara T, Chu T, Ubeda O, Beech W, Cole GM: Selective inhibition of Aβ 42 production by NSAID R-enantiomers. J Neurochem. 2002, 83: 1009-1012. 10.1046/j.1471-4159.2002.01195.x.PubMed

103.

Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, et al: A subset of NSAIDs lower amyloidogenic Aβ 42 independently of cyclooxygenase activity. Nature. 2001, 414: 212-216. 10.1038/35102591.PubMed

104.

Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, Gonzalez-DeWhitt PA, Gelfanova V, Hale JE, May PC, et al: Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ 42 by inhibiting Rho. Science. 2003, 302: 1215-1217. 10.1126/science.1090154.PubMed

105.

Farias GG, Godoy JA, Vazquez MC, Adani R, Meshulam H, Avila J, Amitai G, Inestrosa NC: The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from β-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol Dis. 2005, 18: 176-183. 10.1016/j.nbd.2004.09.012.PubMed

106.

Miranda S, Opazo C, Larrondo LF, Munoz FJ, Ruiz F, Leighton F, Inestrosa NC: The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer's disease. Prog Neurobiol. 2000, 62: 633-648. 10.1016/S0301-0082(00)00015-0.PubMed

107.

Cerpa W, Godoy JA, Alafaro I, Farias GG, Metcalfe MJ, Fuentealba R, Bonansco C, Inestrosa NC: WNT-7a modulates the synaptic vesicle cycle and synaptic transmission in hippocampal neurons. J Biol Chem. 2008, 283: 5918-5927. 10.1074/jbc.M705943200.PubMed

108.

Behl C, Davis JB, Lesley R, Schubert D: Hydrogen peroxide mediates amyloid β protein toxicity. Cell. 1994, 77: 817-827. 10.1016/0092-8674(94)90131-7.PubMed

109.

Santos MJ, Quintanilla RA, Toro A, Grandy R, Dinamarca MC, Godoy JA, Inestrosa NC: Peroxisomal proliferation protects from β-amyloid neurodegeneration. J Biol Chem. 2005, 280: 41057-41068. 10.1074/jbc.M505160200.PubMed

110.

Willson TM, Wahli W: Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol. 1997, 1: 235-241. 10.1016/S1367-5931(97)80015-4.PubMed

111.

Watson GS, Craft S: The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs. 2003, 17: 27-45. 10.2165/00023210-200317010-00003.PubMed

112.

Watson GS, Craft S: Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis. J Neurol Sci. 2006, 245: 21-33. 10.1016/j.jns.2005.08.017.PubMed

113.

Landreth GE, Heneka MT: Anti-inflammatory actions of peroxisome proliferator-activated receptor γ agonists in Alzheimer's disease. Neurobiol Aging. 2001, 22: 937-944. 10.1016/S0197-4580(01)00296-2.PubMed

114.

Feinstein DL: Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther. 2003, 5: 67-73. 10.1089/152091503763816481.PubMed

115.

Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M: Peroxisome proliferator-activated receptor γ is expressed in hippocampal neurons and its activation prevents β-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res. 2005, 304: 91-104. 10.1016/j.yexcr.2004.09.032.PubMed

116.

Fuentealba RA, Farias G, Scheu J, Bronfman M, Marzolo MP, Inestrosa NC: Signal transduction during amyloid-β-peptide neurotoxicity: role in Alzheimer disease. Brain Res Brain Res Rev. 2004, 47: 275-289. 10.1016/j.brainresrev.2004.07.018.PubMed

117.

Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B: Peroxisome Proliferator-Activated Receptor {γ} Induces a Clearance Mechanism for the Amyloid-{β} Peptide. J Neurosci. 2004, 24: 10908-10917. 10.1523/JNEUROSCI.3987-04.2004.PubMed

118.

Pedersen WA, Flynn ER: Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis. 2004, 17: 500-506. 10.1016/j.nbd.2004.08.003.PubMed

119.

Role LW, Berg DK: Nicotinic receptors in the development and modulation of CNS synapses. Neuron. 1996, 16: 1077-1085. 10.1016/S0896-6273(00)80134-8.PubMed

120.

Levin ED, Simon BB: Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl). 1998, 138: 217-230. 10.1007/s002130050667.

121.

Vernino S, Amador M, Luetje CW, Patrick J, Dani JA: Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. Neuron. 1992, 8: 127-134. 10.1016/0896-6273(92)90114-S.PubMed

122.

Banerjee C, Nyengaard JR, Wevers A, de Vos RA, Jansen Steur EN, Lindstrom J, Pilz K, Nowacki S, Bloch W, Schroder H: Cellular expression of α7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease – a stereological approach. Neurobiol Dis. 2000, 7: 666-672. 10.1006/nbdi.2000.0317.PubMed

123.

Kem WR: The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000, 113: 169-181. 10.1016/S0166-4328(00)00211-4.PubMed

Title: The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease
Authors: Nibaldo C Inestrosa
Enrique M Toledo
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Molecular Neurodegeneration / Issue 1/2008
Electronic ISSN: 1750-1326
DOI: https://doi.org/10.1186/1750-1326-3-9

2024 ASCO Annual Meeting

Springer Medicine

The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Oxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein

A novel brain-enriched E3 ubiquitin ligase RNF182 is up regulated in the brains of Alzheimer's patients and targets ATP6V0C for degradation

Molecular signatures of neurodegeneration in the cortex of PS1/PS2 double knockout mice

Prion protein lacks robust cytoprotective activity in cultured cells

Autoimmune-induced preferential depletion of myelin-associated glycoprotein (MAG) is genetically regulated in relapsing EAE (B6 × SJL) F1 mice

Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease